We Are All Sculptra: first-of-its-kind Galderma initiative to demonstrate how everyone can benefit from Sculptra’s regenerative properties Press release
Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™ Press release
Galderma announces U.S. FDA acceptance of RelabotulinumtoxinA Biologics License Application resubmission Press release
Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity Press release
Galderma unveils ‘Wake Up To Restylane’, underscoring Restylane as the ideal hyaluronic acid treatment for always-on natural beauty Press release
Galderma provides update on arbitration case regarding neuromodulator research and development partnership Press release
IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio Press release
TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics Press release
New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis Press release
Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin Press release
